AARP letter to USTR on TPP provisions that would drive up pharmaceutical prices in the U.S.
By AARP
Dear Ambassador Froman:
As the nation’s largest nonprofit, nonpartisan organization representing the interests of Americans age 50 and older and their families, we are writing to comment on the ongoing negotiations surrounding the Trans-Pacific Partnership (TPP) and the issue of market exclusivity for biologic drugs. It is our understanding that market exclusivity is one of the outstanding issues negotiators are working to resolve with the goal of completing the trade agreement before the end of the year. AARP strongly believes the final trade agreement should not bind the U.S. to a 12-year market exclusivity period for brandname biologic drugs.